1221485-69-3

Basic information

• Product Name: 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one
• Synonyms: 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one
• CAS NO: 1221485-69-3
• Molecular Weight: 365.379
• Mol File: 1221485-69-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one(1221485-69-3)
• EPA Substance Registry System: 2-((2,4-difluorophenyl)amino)-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one(1221485-69-3)

Safety Data

• Hazardous Substances Data: 1221485-69-3(Hazardous Substances Data)

Upstream product

• 367-25-9 2,4-difluorophenylamine 
• 871502-87-3 4-bromo-2-formylbenzoic acid 
• 1221486-46-9 2-chloro-7-methoxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one 
• 1353948-58-9 2-(3-chlorophenethenyl)-5-methoxy-benzoic acid 
• 4741-63-3 6-methoxyphthalide 
• 4785-56-2 2-formyl-5-methoxy-benzoic acid 

Downstream Products

• 1221485-83-1 Skepinone-L 
• 1221485-84-2 2-(2,4-difluorophenylamino)-7-[2S-,3-dihydroxypropoxy]-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one 
• 1221485-88-6 2-(2,4-difluorophenylamino)-7-(3-hydroxy-propoxy)-10,11-dihydro-dibenzo[a,d]-cyclohepten-5-one 
• 1221486-16-3 2-((2,4-difluorophenyl)amino)-7-hydroxy-10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-one 

Relevant articles and documents

Design, synthesis, and structure–activity relationship study of potent mapk11 inhibitors

Huntington’s disease (HD) is a rare single-gene neurodegenerative disease, which can only be treated symptomatically. Currently, there are no approved drugs for HD on the market. Studies have found that MAPK11 can serve as a potential therapeutic target f

Design, Synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase

Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of th